Literature DB >> 21703792

Agreement of duplex ultrasonography vs. computed tomography angiography for evaluation of native and in-stent SFA re-stenosis--findings from a randomized controlled trial.

Herbert Langenberger1, Martin Schillinger, Christina Plank, Schila Sabeti, Petra Dick, Manfred Cejna, Johannes Lammer, Erich Minar, Christian Loewe.   

Abstract

BACKGROUND: Multidetector CT angiography (CTA) is a non-invasive imaging technique for evaluation of peripheral vascular disease. CTA might be particularly useful for assessment of intermediate- and long-term morphological outcome after endovascular treatment. Validation of CTA vs. the current imaging standard, colour Doppler ultrasonography (CDUS), for quantification of native and in-stent re-stenosis in the superficial femoral artery (SFA) is required.
METHODS: Seventy randomized patients who underwent stent implantation (n=47) or balloon angioplasty (n=23) underwent 6-month follow-up with CDUS and CTA. CTA was compared with CDUS in both sub-groups of patients in terms of binary re-stenosis (>50% lumen narrowing) and re-occlusion. Agreement between CTA and CDUS was assessed using Kappa (κ) statistics with 95% confidence intervals, and correlation coefficients.
RESULTS: Binary re-stenosis was detected in 16/70 (22.9%) patients by CTA and 17/70 (24.3%) patients by CDUS (κ=0.88, 95% CI: 0.80-0.96). Re-stenosis rates after balloon angioplasty were 39.1% (9/23) on CTA and CDUS (κ=0.82, 95% CI: 0.66-0.98), and after stent implantation 14.9% (7/47) on CTA and 17.0% (8/47) on CDUS (κ=0.92, 95% CI: 0.84-1.00). Re-occlusions were detected in 3/70 (4.3%) patients by both CTA and CDUS (κ=0.65; 95% CI 0.54-0.76). Significant correlations (r=0.85, p<0.001) were noted between degree of re-stenosis on CTA and peak velocity ratio on CDUS. The correlation coefficient was higher in patients after balloon angioplasty (r=0.94, p<0.001) than in patients after stent implantation (r=0.71, p<0.001).
CONCLUSION: CTA and CDUS show excellent agreement for evaluation of native and in-stent re-stenosis after endovascular treatment of SFA obstructions. CTA is an appropriate non-invasive imaging modality for follow-up after endovascular therapy.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21703792     DOI: 10.1016/j.ejrad.2011.05.035

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery disease.

Authors:  Scott Kinlay
Journal:  Circulation       Date:  2013-03-19       Impact factor: 29.690

2.  Abdominal pain in patient with antiphospholipid syndrome-the role of MDCT angiography on visceral blood vessels.

Authors:  Jovica Saponjski; Ljudmila Stojanovich; Jelena Saponjski; Milorad Mirilovic; Dusan Saponjski
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

3.  The role of MSCT angiography in early detection of lower limb arterial lesions in patients with antiphospholipid syndrome.

Authors:  Jovica Saponjski; Ljudmila Stojanovich; Jelena Petrovic; Dusan Saponjski
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

4.  Accuracy of duplex ultrasonography in estimation of severity of peripheral vascular disease.

Authors:  Randall W Franz; Mark A Jump; M Chance Spalding; James J Jenkins
Journal:  Int J Angiol       Date:  2013-09

Review 5.  Peripheral Arterial Disease in Patients with Type 2 Diabetes Mellitus.

Authors:  Sang Youl Rhee; Young Seol Kim
Journal:  Diabetes Metab J       Date:  2015-08       Impact factor: 5.376

6.  128-slice acceletated-pitch dual energy CT angiography of the head and neck: comparison of different low contrast medium volumes.

Authors:  Yu Chen; Huadan Xue; Zheng-yu Jin; Jie Zhang; Hao Sun; Xuan Wang; Zhu-hua Zhang; Da-ming Zhang; Guang-ming Lu; Zhao-qi Zhang; U Joseph Schoepf; Andreas M Bucher; Christopher D Wolla; Yun Wang
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.